Navigation Links
Therapy that heats and destroys bone tumors eases patients' pain
Date:6/2/2013

(CHICAGO) Patients with cancer that has spread to their bones are often treated with radiation therapy to reduce pain. But if that treatment doesn't work, or can't be used again, a second, effective option now exists. Results of a clinical trial on the new therapy, presented by a researcher at Jefferson's Kimmel Cancer Center, is being presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

Mark Hurwitz, MD, Director of Thermal Oncology for the Department of Radiation Oncology at Thomas Jefferson University and Hospital reported that the treatment, magnetic resonance image-guided focused ultrasound (MRIgFU) ablation therapy, significantly reduced pain in 67 percent of patients who received the treatment. The device, known as ExAblate, uses numerous small ultrasound beams designed to converge on a tumor within bone, heat it and destroy it.

"Pain is a common, often debilitating symptom of the spread of cancer to bones. We are pleased to now have a second therapy that can improve a patient's enjoyment of life," says Dr. Hurwitz, who led the clinical trial. A number of cancers spread to bones, and a substantial proportion of patients live for years with these metastases, which can have a profound impact on a patient's quality of life, he adds.

The findings of the trial led to approval of ExAblate last October by the U.S. Food and Drug Administration as second-line therapy for palliation of painful metastatic bone tumors. The first-line therapy is typically radiotherapy.

"The response to ExAblate was as good as radiotherapy, which was notable because it is very unusual to see a second-line treatment with a response rate that is as high as first-line therapy," Dr. Hurwitz says.

He added that use of ExAblate offers several advantages compared to other ablative therapies. "It is non-invasive and provides more detailed anatomic information so that we can visualize the complete beam path to make sure that critical structures such as vessels and nerves are not in the way," Dr. Hurwitz says. "We are also able to monitor the temperature in the tumor as well as in nearby normal tissues so that we do not inadvertently heat normal organs and tissues."

ExAblate has also been approved for treatment of uterine fibroids.

The study led by Dr. Hurwitz is a multicenter, randomized and placebo-controlled phase three clinical trial. The 142 patients enrolled could either not undergo, or had not responded to, radiation treatment.

Three months after ExAblate therapy, 67 percent of treated patients reported significant improvement in pain, compared to 21 percent in the placebo arm. They typically rated their pain as "much improved" or "very much improved," Dr. Hurwitz says. A quality of life assessment also measured significant improvement.

"The treatment is given just once, and a response occurs within days," he says. "There are a lot of patients who could potentially benefit from MR guided focused ultrasound."


'/>"/>

Contact: Danielle Servetnick
danielle.servetnick@jefferson.edu
215-955-2238
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. MGH-led studies shed new light on targeted lung cancer therapy
2. Ayurveda Training in Marma Therapy, Basti, Abhyanga Massage, Swedana, and Ayurvedic Facial Offered in 2013 by the Leading Ayurvedic School in the United States
3. North American Seminars Introduces Responsible CME, a Program That Combined Live Physical Therapy Continuing Education with Online Continuing Education Courses
4. Mainz University obtains new CRC Nanodimensional polymer therapeutics for tumor therapy
5. New therapy is tolerable in lung cancer
6. Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Sixth Annual One Day Sale on Gift Certificates Will Take Place on June 19, 2013
7. Gene Therapy May Protect Against Flu Pandemics
8. Talk Therapy Can Ease Depression, But No Single Type Deemed Best
9. Avatar therapy helps silence voices in schizophrenia
10. Radiotherapy remains the treatment of first choice for high-risk low-grade glioma
11. Researchers provide rationale for use of targeted immunotherapy in sarcomatoid lung carcinomas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest ... the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity drive ... rare and deadly chromosome abnormality. , After struggling since birth with several health ...
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to take certain ... inventor from Austin, Texas, has identified a solution. , She developed a prototype for ... lighting. As such, it eliminates the need to turn on a light when taking ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... CT (PRWEB) , ... October 13, 2017 , ... ... long-term care services, staged a mock evacuation of the facility as part of a ... Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as ...
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
Breaking Medicine Technology: